Traws Pharma ( ($TRAW) ) just unveiled an update. Traws Pharma, Inc. announced the appointment of Iain Dukes as the Interim Chief Executive ...

NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...

Traws Pharma Inc. (TRAW) saw a 4.16% increase in its stock price following its Q1 2025 earnings call, reflecting positive investor sentiment driven by promising updates in its antiviral drug pipeline.

Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing ...

Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates - (March 24, 2025) Traws Pharma, Inc. today announced positive topline results from a study ...

TRAWS PHARMA ($TRAW) posted quarterly earnings results on Monday, March 31st. The company reported earnings of $95.66 per share, beating estimates of -$9.74 by $105. ...

NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical ...